• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
MSB

MESOBLAST LIMITED - Corporate Spotlight

2.86% ! $2.38
Market Cap $3.046B  !
Healthcare Biotechnology
Add to My Watchlist

Mesoblast Limited is an Australia-based company, which is engaged in developing... Mesoblast Limited is an Australia-based company, which is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. It has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of late-stage product candidates. It is developing product candidates for distinct indications based on its remestemcel-L and rexlemestrocel-L allogeneic stromal cell technology platforms. Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid refractory acute graft versus host disease, and biologic-resistant inflammatory bowel disease. Rexlemestrocel-L is being developed for advanced chronic heart failure (REVASCOR) and chronic low back pain (MPC-06-ID). Two products have been commercialized in Japan and Europe by the Company's licensees. It has established commercial partnerships in Europe and China for certain Phase III assets.More

No Corporate Spotlight currently available.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
(20min delay)
Last
$2.38 		Change
-0.070(2.86%) 		Mkt cap ! $3.046B
Open High Low Value Volume
$2.45 $2.48 $2.35 $8.936M 3.711M

Buyers (Bids)

No. Vol. Price($)
4 34219 $2.37
 

Sellers (Offers)

Price($) Vol. No.
$2.39 25304 4
View Market Depth
Last trade - 16.15pm 31/07/2025 (20 minute delay) ?
Last
$2.37 		  Change
-0.070 ( 2.81 %)
Open High Low Volume
$2.42 $2.47 $2.35 1105299
Last updated 15.59pm 31/07/2025 ?
MSB (ASX) Chart

Top Stories

HotCopper Trends: Final day of quarterlies; Larvotto FID & more

Welcome to HotCopper Trends for Thursday 31st of July @ the last day ahead of Washington’s apparent move to un-pause sweeping tariffs. But that’s neither here nor there. (Nor is the fact that this is the last time we should have to deal with a slog of quarterlies, ...
Sun Silver unveils Maverick Springs assay results Sun Silver (ASX:SS1) has reported antimony assay results from its ongoing re-assay program at its Maverick Springs Silver-Gold Project in Nevada, USA.The latest assays from historical drillhole MR103 returned a broad intercept of 59 metres including antimony grades of 7.8%. A second hole, MR092, ...
Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign Infini Resources’ newly appointed CEO, Rohan Bone joins The Market Online to discuss strategy moving forward. Join the discussion. See what HotCopper users are saying about Infini Resources and be part of the conversations that move the markets.The material provided in this articl...
Investor education equals superior returns @Investor education can lead to superior returns”. As the founder of The Stock Network, Lel Smits is determined to elevate investor education for all Aussie investors.I caught up with Lel to talk all things investor education, and why investor education is a great activity f...
Larvotto hits "go" on Hillgrove Project Larvotto Resources (ASX:LRV) has ticked 1.6% higher in intra-day trade after hitting @go” on its Hillgrove Antimony-Gold Project near Armidale in northern New South Wales. The board approved a Final Investment Decision (FID) following a fresh injection of capital to fully fu...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.